Agranulocytosis secondary to propylthiouracil

Khaliq, Waseem; Ponor, Lucia; Cheripalli, Praveen; Tangella, Krishnarao; Chaudhry, Zoobia W

doi:10.1093/qjmed/hcr168

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Review of the literature of reported cases of agranulocytosis between 1999 and 2013 identified 80 cases where the presenting symptoms were described [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37]. Fever (93.8%), sore throat (68.7%) and chills (21.2%) were the commonest presenting symptoms.…”

Section: Resultsmentioning

confidence: 99%

Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis

Robinson¹,

Richardson²,

Hickey³

et al. 2014

Eur Thyroid J

View full text Add to dashboard Cite

Background: Agranulocytosis is a serious side effect of antithyroid drugs. Objective: To ascertain the knowledge of patients and review the quality of information available on the internet. Methods: A questionnaire survey was performed for patients receiving antithyroid drugs. Patients attending endocrine clinics who were receiving antithyroid drug treatment (group A, n = 33) were interviewed. A further national cohort of patients (group B, n = 100) treated with antithyroid drugs, participated in an online survey. Results: 60.9% of responders were not aware of the common symptoms of agranulocytosis. 18.6% had never received any information about side effects. Of the 108 patients who recalled receiving information, 30% rated the quality as ‘poor' or ‘not good at all'. Structured interviews of group A patients revealed that almost half (45.5%, 15/33) had experienced symptoms that could be indicative of agranulocytosis, but only 53.3% (8/15) had a blood count checked. A review of 20 selected patient information internet sites revealed a significant variation in advice given to patients. Conclusions: Inadequate knowledge about agranulocytosis among patients receiving antithyroid drug treatment is common. The available information on the internet is variable and inconsistent.

show abstract

Section: Resultsmentioning

confidence: 99%

Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis

Robinson¹,

Richardson²,

Hickey³

et al. 2014

Eur Thyroid J

View full text Add to dashboard Cite

show abstract

“…Daha nadiren kolestatik sarılık, hepatit, lupus benzeri sendrom, hipergamaglobulinemi ve hematolojik yan etkiler ortaya çıkabilmektedir. Hematolojik yan etkilerden agranülositoz, nötropeni ve aplastik anemi nadiren görülmesine rağmen tedavi edilmezse ölüme yol açabilmektedir (5,6). Agranülositoz seçici olarak nöt-rofil sayısında belirgin azalma (sıklıkla 0.5x10 3 /mm 3 olması) ile birlikte ateş ve/veya enfeksiyonun işaretlerinin bulunmasıdır (7).…”

Section: Discussionunclassified

“…PTU kullanımına bağlı agranülositozun insidansı %0.37'dir (8). Sıklıkla ilk 3 ay içerisinde görülme-sine rağmen daha geç dönemde de ortaya çıkabileceği bildirilmiştir (5). Her ne kadar metimazolun kullanım dozu ile agranülositoz gelişim riski arasında ilişki gösterilmişse de bu ilişki PTU için geçerli değildir (9).…”

Section: Discussionunclassified

“…Antitiroid ilaç kullanımına bağlı ortaya çıkan agranülosi-tozu önlemek için rutin kan sayımı takibi önerilmemek- tedir. Bunun yerine hastaların boğaz ağrısı ve ateş yük-sekliği olduğunda ilacı bırakarak sağlık merkezine baş-vurmaları konusunda uyarılmaları daha iyi bir yöntem olarak önerilmektedir (5,15). Sonuç olarak, antitiroid ilaçlar hipertiroidinin tedavisinde sık kullanılmakta ve nadir de olsa önemli yan etkilere neden olmaktadırlar.…”

Section: Discussionunclassified

See 1 more Smart Citation

Agranulocytosis due to propylthiouracil treatment: a case report

Sabuncu¹,

Eren²,

Kurnaz³

et al. 2015

Bakirkoy

View full text Add to dashboard Cite

Agranulocytosis due to propylthiouracil treatment: a case report Propylthiouracil (PTU) is a commonly used anti-thyroid drug in the treatment of hyperthyroidism due to Graves disease. Life-threatening complications such as agranulocytosis may occur during the treatment of PTU. We present a case of hyperthyroidism due to Graves disease who was admitted with the typical signs of agranulocytosis at two months after the initiation of therapy and treated successfully with granulocyte colony stimulating factor.

show abstract

Propylthiouracil

2013

Reactions Weekly

View full text Add to dashboard Cite

Agranulocytosis secondary to propylthiouracil

Cited by 6 publications

References 11 publications

Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis

Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis

Agranulocytosis due to propylthiouracil treatment: a case report

Propylthiouracil

Contact Info

Product

Resources

About